Longitudinal Whole-Brain N-Acetylaspartate Concentration in Healthy Adults

References

1. 1.↵
   1. Lin AP,
   2. Tran TT,
   3. Ross BD

   . Impact of evidence-based medicine on magnetic resonance spectroscopy. NMR Biomed 2006; 19: 476– 83

   CrossRefPubMed
2. 2.↵
   1. Filippi M,
   2. Agosta F

   . Magnetic resonance techniques to quantify tissue damage, tissue repair, and functional cortical reorganization in multiple sclerosis. Prog Brain Res 2009; 175: 465– 82

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Martinez-Bisbal MC,
   2. Celda B

   . Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nuclear Med Mol Imaging 2009; 53: 618– 30
4. 4.↵
   1. Miller BL

   . A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991; 4: 47– 52

   PubMedWeb of Science
5. 5.↵
   1. Miller DH

   . Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004; 1: 284– 94

   Abstract/FREE Full Text
6. 6.↵
   1. Birken DL,
   2. Oldendorf WH

   . N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13: 23– 31

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Baslow MH

   . Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 2000; 75: 453– 59

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Baslow MH

   . Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain's “operating system”: how NAA metabolism supports meaningful intercellular frequency-encoded communications. Amino Acids 2010; 39: 1139– 45

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Benarroch EE

   . N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 2008; 70: 1353– 57

   FREE Full Text
10. 10.↵
    1. Danielsen EA,
    2. Ross B

    . Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York: Marcel Dekker; 1999
11. 11.↵
    1. Ross BD,
    2. Bluml S

    . Magnetic resonance spectroscopy of the human brain. Anat Rec 2001; 265: 54– 84

    CrossRefPubMed
12. 12.↵
    1. Schott JM,
    2. Frost C,
    3. Macmanus DG,
    4. et al

    . Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain 2010; 133: 3315– 22

    Abstract/FREE Full Text
13. 13.↵
    1. Wild EJ,
    2. Fox NC

    . Serial volumetric MRI in Parkinsonian disorders. Mov Disord 2009; 24 (suppl 2): S691– 98

    CrossRefPubMed
14. 14.↵
    1. Sormani MP,
    2. Bruzzi P,
    3. Comi G,
    4. et al

    . MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002; 58: 417– 21

    Abstract/FREE Full Text
15. 15.↵
    1. Filippi M,
    2. Grossman RI

    . MRI techniques to monitor MS evolution: the present and the future. Neurology 2002; 58: 1147– 53

    Abstract/FREE Full Text
16. 16.↵
    1. Narayana PA,
    2. Doyle TJ,
    3. Lai D,
    4. et al

    . Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56– 71

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Wolinsky JS,
    2. Narayana PA

    . Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr Opin Neurol 2002; 15: 247– 51

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Brooks WM,
    2. Friedman SD,
    3. Stidley CA

    . Reproducibility of 1H-MRS in vivo. Magn Reson Med 1999; 41: 193– 97

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Marshall I,
    2. Wardlaw J,
    3. Cannon J,
    4. et al

    . Reproducibility of metabolite peak areas in 1H MRS of brain. Magn Reson Imaging 1996; 14: 281– 92

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Bokde AL,
    2. Teipel SJ,
    3. Zebuhr Y,
    4. et al

    . A new rapid landmark-based regional MRI segmentation method of the brain. J Neurol Sci 2002; 194: 35– 40

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Inglese M,
    2. Ge Y,
    3. Filippi M,
    4. et al

    . Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004; 21: 1825– 29

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Rigotti DJ,
    2. Inglese M,
    3. Gonen O

    . Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007; 28: 1843– 49

    Abstract/FREE Full Text
23. 23.↵
    1. Hu J,
    2. Javaid T,
    3. Arias-Mendoza F,
    4. et al

    . A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy. J Magn Reson B 1995; 108: 213– 19

    CrossRefPubMed
24. 24.↵
    1. Ashburner J,
    2. Friston K

    . Multimodal image coregistration and partitioning–a unified framework. Neuroimage 1997; 6: 209– 17

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Ashburner J,
    2. Friston KJ

    . Voxel-based morphometry–the methods. Neuroimage 2000; 11: 805– 21

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Gonen O,
    2. Viswanathan AK,
    3. Catalaa I,
    4. et al

    . Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998; 40: 684– 89

    PubMedWeb of Science
27. 27.↵
    1. Behar KL,
    2. Rothman DL,
    3. Spencer DD,
    4. et al

    . Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magnetic Reson Med 1994; 32: 294– 302

    CrossRef
28. 28.↵
    1. Baslow MH

    . N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 2003; 28: 941– 53

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Moffett JR,
    2. Ross B,
    3. Arun P,
    4. et al

    . N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89– 131

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Gonen O,
    2. Catalaa I,
    3. Babb JS,
    4. et al

    . Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000; 54: 15– 19

    Abstract/FREE Full Text
31. 31.↵
    1. Benedetti B,
    2. Rigotti DJ,
    3. Liu S,
    4. et al

    . Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007; 28: 72– 75

    Abstract/FREE Full Text
32. 32.↵
    1. Ciumas C,
    2. Montavont A,
    3. Ryvlin P

    . Magnetic resonance imaging in clinical trials. Curr Opin Neurol 2008; 21: 431– 36

    PubMedWeb of Science
33. 33.↵
    1. Jack CR Jr.,
    2. Slomkowski M,
    3. Gracon S,
    4. et al

    . MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60: 253– 60

    Abstract/FREE Full Text
34. 34.↵
    1. Comi G,
    2. Filippi M

    . Clinical trials in multiple sclerosis: methodological issues. Curr Opin Neurol 2005; 18: 245– 52

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Rovaris M,
    2. Filippi M

    . Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999; 12: 337– 44

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Simmons ML,
    2. Frondoza CG,
    3. Coyle JT

    . Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37– 45

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Jenkins BG,
    2. Klivenyi P,
    3. Kustermann E,
    4. et al

    . Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 2000; 74: 2108– 19

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Moffett JR,
    2. Namboodiri MA,
    3. Cangro CB,
    4. et al

    . Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991; 2: 131– 34

    PubMedWeb of Science
39. 39.↵
    1. Coffey CE,
    2. Wilkinson WE,
    3. Parashos IA,
    4. et al

    . Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. Neurology 1992; 42: 527– 36

    Abstract/FREE Full Text
40. 40.↵
    1. Pfefferbaum A,
    2. Mathalon DH,
    3. Sullivan EV,
    4. et al

    . A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol 1994; 51: 874– 87

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Scahill RI,
    2. Frost C,
    3. Jenkins R,
    4. et al

    . A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 2003; 60: 989– 94

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Rigotti DJ,
    2. Inglese M,
    3. Babb JS,
    4. et al

    . Serial whole-brain N-acetylaspartate con-centration in healthy young adults. AJNR Am J Neuroradiol 2007; 28: 1650– 51

    Abstract/FREE Full Text
43. 43.↵
    1. Hövener JB,
    2. Rigotti DJ,
    3. Amann A,
    4. et al

    . Whole-brain N-acetylaspartate MR spectroscopic quantification: performance comparison of metabolite versus lipid nulling. AJNR Am J Neuroradiol 2008; 29: 1441– 45

    Abstract/FREE Full Text
44. 44.↵
    1. Greco JB,
    2. Sakaie KE,
    3. Aminipour S,
    4. et al

    . Magnetic resonance spectroscopy: an in vivo tool for monitoring cerebral injury in SIV-infected macaques. J Med Primatol 2002; 31: 228– 36

    CrossRefPubMed
45. 45.↵
    1. Filippi M,
    2. Bozzali M,
    3. Rovaris M,
    4. et al

    . Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433– 37

    Abstract/FREE Full Text